None listed
Conditions
Brief summary
This study aims to provide a dosimetric comparison between plans using the Stereotactic Body Radiation Therapy Normal Tissue Objective (SBRT NTO) feature in Eclipse version 18 (v18.0) planning system and those using the standard NTO settings currently utilised in our department. Who is it for? Ten lung and ten nodal/bone metastasis stereotactic body radiation therapy (SBRT) plans that were previously treated at our institution from July 2022 until December 2024. The study may include patients with one or two targets. Study details: Once the participants are deemed eligible they will be randomly selected and anonymised. The de-identified datasets of the selected patients and corresponding plans will be sent to an Eclipse v18.0 test system where they will be replanned using the SBRT normal tissue objective (NTO) feature by the PI. After replanning, the impact of SBRT NTO on plan metrics for lung and nodal/bone metastasis SBRT plans and the effectiveness of Eclipse 18 will be compared to previously clinically accepted plan. It is hope that the results from this study will provide a solution to automate the process of enforcing sharp dose fall-off around the target and eliminates the need for time-consuming manual contouring of optimisation structures.
Interventions
Ten lung and ten nodal/bone metastasis stereotactic body radiation therapy (SBRT) plans that were previously treated at our institution from July 2022 until December 2024 will be randomly selected and anonymised. There will be no direct involvement from patients as the study is collecting data retrospectively from existing medical records, and therefore, no treatment given to participants as they have already finished their course of treatment - only their datasets and plans will be used for the
Ten lung and ten nodal/bone metastasis stereotactic body radiation therapy (SBRT) plans that were previously treated at our institution from July 2022 until December 2024 will be randomly selected and anonymised. There will be no direct involvement from patients as the study is collecting data retrospectively from existing medical records, and therefore, no treatment given to participants as they have already finished their course of treatment - only their datasets and plans will be used for the study. The study may include patients with one or two targets. The de-identified datasets of the selected patients and corresponding plans will be sent to an Eclipse v18.0 test system where they will be replanned using the SBRT normal tissue objective (NTO) feature by the Principal Investigator (PI). The plans will maintain all parameters, such as arc arrangement, constant. The sole modification will involve changing the NTO setting from our manually optimised settings to the SBRT NTO within the optimiser. All plans will be optimised in ‘automatic mode’ with an intermediate dose calculation using the Acuros calculation algorithm. The optimiser will not be paused during optimisation nor re-optimised following final dose calculation.
Sponsors
Helen Truong - Canberra Health Services
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Treated for SBRT nodal/ bone and lung metastasis from July 2022 to December 2024. SBRT volumes containing 1 or 2 targets.
Exclusion criteria
None
Outcome results
None listed